Results from studies addressing age-related patterns of cancer care have found evidence of unjustified differences in management between younger and older patients.We examined associations between ...
We thank Kocak for the interest in our work (Kocak. Letter to the Editor Acta Oncologica 2021). We agree that BMI is a factor of importance that may influence cancer outcomes since both underweight...
Objectives: A substantial proportion of patients with cancer use complementary and alternative medicine (CAM), yet the topic is rarely addressed in clinical encounters. This communication gap may affect patient safety, trust and participation in care. This study aimed to explore how patients experience encounters with healthcare professionals when using CAM alongside oncological or palliative care. Design: An exploratory qualitative study using semi-structured interviews and qualitative content analysis. Setting: Oncology and palliative care services in a Swedish healthcare region. Participants: 19 adult patients with cancer who used CAM alongside conventional cancer care and were purposively recruited from a larger regional survey. Results: Patients described continuously assessing whether it was appropriate to mention CAM. Subtle verbal and non-verbal cues from healthcare professionals shaped perceptions of what was considered legitimate within clinical encounters, often leading to silence or withdrawal. In contrast, neutral or respectful responses facilitated trust and dialogue. Openness regarding CAM was not fixed but adjusted from one encounter to another, influenced by interpersonal interactions, organisational conditions and prevailing evidence norms. Participants expressed a need for respectful dialogue, basic competence among healthcare staff and practical support for safe CAM use, without implying endorsement. Conclusions: Patients who use CAM navigate a healthcare context characterised by shifting relational cues and structural constraints that influence communication. Safe, person-centred care may be supported by normalising discussions about CAM, improving basic staff knowledge and facilitating open dialogue. Such measures may promote trust, improve communication and reduce risks associated with undisclosed CAM use.
Erythropoietin is an effective treatment for anemia in patients with various types of cancers, but few studies have evaluated the benefit of treatment in advanced breast cancer. In this multicenter study, we investigated the influence of two different doses of epoetin-beta on the level of hemoglobin, the need for blood transfusion, quality of life and safety aspects in patients with metastatic breast cancer. A total of 180 patients were randomized to receive either 1000 IE or 5000 IE epoetin-beta subcutaneously three times per week for 24 weeks. An increase of 20 g/L was defined as a positive hemoglobin response. Blood transfusions were given, if clinically indicated. Additional laboratory values and adverse events were recorded. Quality of life was measured with the aid of the EORTC QLQ-C30 questionnaire. Hemoglobin levels increased significantly in both groups. In the high-dose group, the initial mean Hb value was 98 g/L (64-110), which increased to 121 g/L (83-165) by week 24. In the low-dose group, the mean Hb value was 99 g/L (77-110.5) and by week 24 it was 116 g/L (81-144). The majority of patients who responded to treatment did so during the first four weeks. After 4 weeks, 7 patients in the low-dose group and 24 patients in the high-dose group had increased their Hb values by more than 20 g/L. The need for transfusion was low and did not differ between the groups. Quality of life was significantly enhanced in both groups, and there was no difference in the global quality of life between the two study arms. Epoetin-beta is a well-tolerated, safe and effective treatment of anemia in patients with metastatic breast cancer. There were significant improvements in Hb levels and quality of life in both groups.